Lumos Pharma Analyst Ratings
Lumos Pharma's LUM-201 Receives 'Buy' Rating on Strong Market Position and Promising Trial Outcomes
Lumos Pharma Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
Lumos Pharma Analyst Ratings
Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Lumos Pharma Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Rhythm Pharmaceuticals (RYTM)
Promising Results and Buy Rating for Lumos Pharma's Groundbreaking Growth Hormone Stimulant: LUM-201
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Lumos Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Insmed (INSM) and Lumos Pharma (LUMO)
Cantor Fitzgerald Reiterates Overweight on Lumos Pharma, Maintains $10 Price Target
Lumos Pharma Analyst Ratings
Lumos Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: REPRO-MED Systems (KRMD), Lumos Pharma (LUMO) and Curaleaf Holdings (OtherCURLF)
Oppenheimer Adjusts Lumos Pharma Price Target to $17 From $18, Maintains Outperform Rating
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Lumos Pharma Analyst Ratings
No Data